19 May 2013
Keywords: exelixis, receive, up, 157m, wyeth, fxr, deal
Article | 09 January 2006
US biotechnology firm Exelixis has signed a license agreement with drug major Wyeth related to compounds targeting the farnesoid X ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
9 January 2006
16 January 2006
17 May 2013
© 2013 thepharmaletter.com